Table 2 The use of vasoactive medications, their relationship with 90-day mortality, and maximum rates and duration of infusion
Overall use n (%) | 90-Day mortality | |||||
|---|---|---|---|---|---|---|
When treated with the respective agent | When treated without the respective agent | P | Maximum infusion rate, μg/kg/min, median (IQR) | Infusion duration, h | ||
Vasopressors | ||||||
Noradrenaline | 162 (75) | 47 % | 24 % | 0.003 | 0.31 (0.16–0.63) | 42 (20–72) |
Adrenaline | 46 (21) | 74 % | 32 % | <0.001 | 0.22 (0.10–0.36) | 18 (6–41) |
Dopamine | 56 (26) | 43 % | 41 % | 0.8 | 7.5 (3.2–11.1) | 25 (8–71) |
Vasopressin/terlipressin | 8 (4) | 88 % | 39 % | 0.01 | NA | 20 (9–29) |
Inotropes | ||||||
Dobutamine | 105 (49) | 48 % | 35 % | 0.06 | 9.8 (6.5–16.7) | 49 (16–72) |
Levosimendan | 52 (24) | 33 % | 44 % | 0.15 | 0.13 (0.10–0.22) | 40 (28–51) |
PDE3i | 9 (4) | 33 % | 42 % | 0.6 | NA | 43 (21–72) |
Combinations | ||||||
Vasopressor combination | 65 (30) | 66 % | 30 % | <0.001 | - | - |
Dobutamine and vasopressor(s) | 84 (39) | 57 % | 31 % | <0.001 | - | - |
Levosimendan and vasopressor(s) | 47 (21) | 34 % | 44 % | 0.3 | - | - |